IJTLD openPub Date : 2025-01-01DOI: 10.5588/ijtldopen.24.0440
T Diefenbach-Elstob, S Tabrizi, P Rivest, A Benedetti, L Azoulay, K Schwartzman, C Greenaway
{"title":"Risk of TB disease in individuals with cancer.","authors":"T Diefenbach-Elstob, S Tabrizi, P Rivest, A Benedetti, L Azoulay, K Schwartzman, C Greenaway","doi":"10.5588/ijtldopen.24.0440","DOIUrl":"10.5588/ijtldopen.24.0440","url":null,"abstract":"<p><strong>Background: </strong>Cancer increases the risk of developing TB disease; however, there are limited data on the magnitude of risk by cancer type and timing after diagnosis of cancer in low TB incidence settings.</p><p><strong>Methods: </strong>We conducted a nested case-control study of persons in Quebec between 1993 and 2017, including people with TB disease and matched controls. Conditional logistic regression was used to estimate adjusted odds ratios (aORs) of developing TB among people with cancer overall, by sub-type, and by time from cancer to TB diagnosis.</p><p><strong>Results: </strong>There were 4,283 people with TB disease and 268,420 matched controls. The median age for people with TB disease and controls was respectively 46 years (IQR 30-67) and 36 years (24-47). Prior exposure to cancer was associated with TB disease (aOR 6.3, 95% CI 5.3-7.6). The risk of TB diagnosis was highest within 3 months of cancer diagnosis (aOR 26.6, 95% CI 19.6-36.2), with 60% of diagnoses of TB disease occurring within 6 months of cancer diagnosis.</p><p><strong>Conclusion: </strong>Risk of TB varies over time and by cancer type. Screening and treatment should be considered for potentially preventable TB (diagnosed more than 6 months post-cancer), particularly in those with respiratory, haematologic, and head and neck cancers.</p>","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 1","pages":"45-52"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IJTLD openPub Date : 2025-01-01DOI: 10.5588/ijtldopen.24.0593
M Nash, A Deluca, E Lessem, N West, L McKenna, E V McConnell, K Angami, R Herrera, A Makone, G E Velásquez, R E Chaisson, P P J Phillips
{"title":"Person-centred language for describing stratified approaches to TB treatment.","authors":"M Nash, A Deluca, E Lessem, N West, L McKenna, E V McConnell, K Angami, R Herrera, A Makone, G E Velásquez, R E Chaisson, P P J Phillips","doi":"10.5588/ijtldopen.24.0593","DOIUrl":"10.5588/ijtldopen.24.0593","url":null,"abstract":"","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 1","pages":"56-58"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IJTLD openPub Date : 2025-01-01DOI: 10.5588/ijtldopen.24.0250
A J Marthinus, D T Wademan, Z Saule, Y Hirsch-Moverman, L Viljoen, J Winckler, L van der Laan, M Palmer, S L Barnabas, R Boyd, A C Hesseling, G Hoddinott
{"title":"Children and providers' perspectives on once-weekly rifapentine and isoniazid TB preventive therapy.","authors":"A J Marthinus, D T Wademan, Z Saule, Y Hirsch-Moverman, L Viljoen, J Winckler, L van der Laan, M Palmer, S L Barnabas, R Boyd, A C Hesseling, G Hoddinott","doi":"10.5588/ijtldopen.24.0250","DOIUrl":"10.5588/ijtldopen.24.0250","url":null,"abstract":"<p><strong>Background: </strong>TB preventive treatment (TPT) prevents the development of TB disease in individuals at risk of progression from infection to disease. However, implementation of TPT for children is poor in most high-burden settings. The long duration and pill burden of the 6-month once-daily isoniazid regimen (6H) pose significant barriers to completion. We aimed to understand children's, caregivers', and healthcare providers' experiences of the 12-week once-weekly rifapentine and isoniazid (3HP) regimen using a dispersible tablet formulation in South Africa.</p><p><strong>Methods: </strong>Serial, in-depth qualitative interviews with 20 child-caregiver dyads, including 5 children living with HIV (CLWH) and 9 healthcare providers across two study sites implementing a pharmacokinetic and safety trial of 3HP, were analysed deductively.</p><p><strong>Results: </strong>Of those with experience using both 3HP and 6H, caregivers and healthcare providers preferred 3HP, and study participants reported that the 3HP formulation was more palatable and easier to prepare and administer. Caregivers and healthcare providers were concerned about optimally integrating 3HP into routine care, primarily due to its once-weekly administration. Children with HIV preferred the once-daily 6H regimen for its ease of use with their daily antiretroviral therapy.</p><p><strong>Conclusions: </strong>3HP reduced the administration burden for children and their caregivers. Once weekly, 3HP dosing will require education and adherence support to ensure completion.</p>","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 1","pages":"13-18"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IJTLD openPub Date : 2025-01-01DOI: 10.5588/ijtldopen.24.0357
A Nowinski, E Augustynowicz-Kopeć, J Garnczarek, A Halicka, M Koszela, W Litwiniuk, D Maj, I Mazur, J Niestrój-Ostrowska, R Podlasin, A Regulska, M Wielopolska, J Wyrwiński, S Wesołowski, M Korzeniewska-Koseła
{"title":"The impact of the war in Ukraine on the prevalence of MDR/RR-TB in Poland.","authors":"A Nowinski, E Augustynowicz-Kopeć, J Garnczarek, A Halicka, M Koszela, W Litwiniuk, D Maj, I Mazur, J Niestrój-Ostrowska, R Podlasin, A Regulska, M Wielopolska, J Wyrwiński, S Wesołowski, M Korzeniewska-Koseła","doi":"10.5588/ijtldopen.24.0357","DOIUrl":"10.5588/ijtldopen.24.0357","url":null,"abstract":"<p><strong>Background: </strong>The 2022 invasion of Ukraine by the Russian Federation triggered a refugee crisis, affecting the multidrug-/rifampicin-resistant TB (MDR/RR-TB) prevalence in neighbouring countries. This study examines the epidemiological trends and characteristics of MDR/RR-TB patients in Poland, focusing on the relative contribution of Ukrainian refugees.</p><p><strong>Methods: </strong>Data from the Polish National Tuberculosis Registry and EPIC Project database, covering MDR/RR-TB cases reported between 2010 and Q1 2024, were analysed.</p><p><strong>Results: </strong>The study included 794 MDR/RR-TB cases, showing a demographic shift post-2022. During the 10-year period up to 2021, a median of 48 MDR/RR-TB cases were reported annually in Poland. After 2022, these numbers doubled: 104 cases were reported in 2022 and 101 cases in 2023. Simultaneously, the number of Ukrainian MDR/RR-TB patients increased from 77 (13%) during 2010-2021 to 127 (58%) from 2022 to Q1 2024.</p><p><strong>Conclusion: </strong>Poland is observing an increased number of cases of MDR/RR-TB associated with the large number of displaced Ukrainian citizens who are now residing in Poland. There is a need to monitor the epidemiology of MDR/RR-TB and seek optimal screening and management strategies for TB among refugees from countries with high MDR/RR-TB incidence in Poland and Europe.</p>","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 1","pages":"6-12"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IJTLD openPub Date : 2024-12-01DOI: 10.5588/ijtldopen.24.0530
E Pontali, R Centis
{"title":"TB survivors: why curing TB is sometimes not enough.","authors":"E Pontali, R Centis","doi":"10.5588/ijtldopen.24.0530","DOIUrl":"10.5588/ijtldopen.24.0530","url":null,"abstract":"<p><p>It is now well understood that the effect of TB does not always end when a patient completes a successful course of treatment. Successful treatment is by definition a microbiological cure, but people may continue to suffer the consequences of TB for months or years after treatment. For example, ongoing health challenges can present in the form of post-TB lung disease (PTLD), and there is a high incidence of TB-related symptoms associated with disability in other domains. We discuss an article in this issue of the <i>Journal</i> that explores the experiences of adult TB survivors, which further expands our understanding of this condition.</p>","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 12","pages":"531-532"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11636497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IJTLD openPub Date : 2024-12-01DOI: 10.5588/ijtldopen.24.0141
A K McDonald, D Nakkonde, P Kaggwa, S Zalwango, A Joseph, E Buregyeya, J N Sekandi
{"title":"Prevalence of TB-related symptoms and self-reported disability among adult TB survivors.","authors":"A K McDonald, D Nakkonde, P Kaggwa, S Zalwango, A Joseph, E Buregyeya, J N Sekandi","doi":"10.5588/ijtldopen.24.0141","DOIUrl":"10.5588/ijtldopen.24.0141","url":null,"abstract":"<p><strong>Background: </strong>Growing evidence suggests that post-TB-related morbidity occurs often among TB survivors, but there is limited epidemiological data on the burden of symptoms and disability after successful completion of treatment. We evaluated the prevalence of TB-related symptoms, self-reported disability, and factors associated with disability among adult TB survivors who recently completed treatment in Uganda.</p><p><strong>Methods: </strong>Between January 2022 and October 2023, we conducted a study of adults who completed treatment for drug-susceptible TB in Kampala, Uganda. We collected data on demographics, TB-related symptoms, HIV status, and disability measured using the World Health Organization Disability Assessment Schedule (WHODAS 2.0).</p><p><strong>Results: </strong>Of the 200 participants, the median age was 33.0 years (IQR 26-44.5); 52.5% were male, and 23% were HIV-infected. The prevalence of TB symptoms was 58%, and self-reported disability was 83.5%. Factors significantly associated with disability were having completed treatment within the last 6-8 months and experiencing TB symptoms (aOR 2.87, <i>P</i> = 0.04; and aOR 2.51, <i>P</i> = 0.03, respectively), after adjusting for age, sex and HIV status.</p><p><strong>Conclusions: </strong>TB-related symptoms and self-reporting of any disability were highly prevalent in the study population. There is a need for further longitudinal evaluation and considerations to expand the continuum of care and support to improve the quality of life for TB survivors post-TB treatment.</p>","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 12","pages":"540-546"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11636498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IJTLD openPub Date : 2024-12-01DOI: 10.5588/ijtldopen.24.0428
J Sebastian, I D Olaru, A Giannakis, M Arentz, S V Kik, M Ruhwald, S Linsen, G Günther, P Wolf, F J Herth, T Weber, C M Denkinger
{"title":"Detection of other pathologies when utilising computer-assisted digital solutions for TB screening.","authors":"J Sebastian, I D Olaru, A Giannakis, M Arentz, S V Kik, M Ruhwald, S Linsen, G Günther, P Wolf, F J Herth, T Weber, C M Denkinger","doi":"10.5588/ijtldopen.24.0428","DOIUrl":"10.5588/ijtldopen.24.0428","url":null,"abstract":"<p><strong>Background: </strong>Computer-aided detection (CAD) tools for TB detection have the potential to enable screening programmes and reduce the diagnostic gap in settings where access to radiologists is limited. However, there are concerns that other common chest X-ray (CXR) abnormalities not due to TB may be missed.</p><p><strong>Methods: </strong>We assessed the performance of three commercialised CAD tools (qXR, INSIGHT CXR and DrAID<sup>TM</sup> TB XR) to detect common non-TB abnormalities against readings with a standardised annotation guide by an expert radiologist. More than 20 well-characterised diagnoses besides TB significant in TB high-burden countries were examined.</p><p><strong>Results: </strong>The 517 CXRs included were deemed abnormal by the three CAD with a sensitivity of respectively 97% (95% CI 95-98), 94% (95% CI 91-95), and 87% (95% CI 84-90) for INSIGHT CXR, qXR, and DrAID. The CAD generally detected abnormalities in patients with critical diagnoses such as lung cancer or heart failure. Performance for detecting other abnormalities was variable.</p><p><strong>Conclusion: </strong>This study showed that the three CAD tools identified CXRs as abnormal when diseases other than TB were present. Our findings alleviate ethical concerns of missing abnormalities other than TB when using commercially available CAD for TB screening and show their potential broader applicability.</p>","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 12","pages":"533-539"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11636493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IJTLD openPub Date : 2024-12-01DOI: 10.5588/ijtldopen.24.0454
P Kunč, J Fábry, P Ferenc, T Strachan, M Matiščáková, I Solovič, R Péčová, M Dohál
{"title":"Disseminated TB associated with acute severe malnutrition in a Roma child.","authors":"P Kunč, J Fábry, P Ferenc, T Strachan, M Matiščáková, I Solovič, R Péčová, M Dohál","doi":"10.5588/ijtldopen.24.0454","DOIUrl":"10.5588/ijtldopen.24.0454","url":null,"abstract":"","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 12","pages":"571-574"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11636492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IJTLD openPub Date : 2024-12-01DOI: 10.5588/ijtldopen.24.0441
T Nii, K Fujiwara, T Kobayashi, E Hagiwara, K Fukushima, K Morimoto, K Tsuyuguchi, T Ogura, H Kida
{"title":"Serodiagnosis of <i>M</i>. <i>abscessus</i> species pulmonary disease using anti-glycopeptidolipid-core IgA antibody.","authors":"T Nii, K Fujiwara, T Kobayashi, E Hagiwara, K Fukushima, K Morimoto, K Tsuyuguchi, T Ogura, H Kida","doi":"10.5588/ijtldopen.24.0441","DOIUrl":"10.5588/ijtldopen.24.0441","url":null,"abstract":"","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 12","pages":"575-577"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11636494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IJTLD openPub Date : 2024-12-01DOI: 10.5588/ijtldopen.24.0413
S Kang, J E Schmidt, I Chen, S Tiberi
{"title":"Treatment outcomes in NTM-PD in a high TB burden context.","authors":"S Kang, J E Schmidt, I Chen, S Tiberi","doi":"10.5588/ijtldopen.24.0413","DOIUrl":"10.5588/ijtldopen.24.0413","url":null,"abstract":"<p><strong>Background: </strong>Non-tuberculous mycobacterial (NTM) pulmonary disease (PD) is a significant concern in China, compounding the existing burden of TB. This review aims to summarise the treatment outcomes for NTM-PD in China.</p><p><strong>Methods: </strong>We reviewed the evidence on NTM-PD, including treatment regimens and clinical outcomes, from 17 studies identified through screening of three Chinese biomedical databases.</p><p><strong>Results: </strong>Antimicrobial treatment showed a microbiological cure rate ranging from 17.2% to 60.0% in studies with ≥50 NTM-PD patients, with lower rates observed among older and malnourished patients. The <i>Mycobacterium chelonae</i> abscessus group (MC-AG) and <i>Mycobacterium avium</i>-intracellulare complex (MAC) were the most prevalent NTM species in China. Higher microbiological cure rates were seen in MAC PD compared with MC-AG PD. The addition of cefoxitin and linezolid improved culture conversion rates in MC-AG-infected patients. One study (<i>n</i> = 24) demonstrated that resecting lesions and chemotherapy led to more favourable clinical outcomes.</p><p><strong>Conclusion: </strong>Treatment regimens recommended in Chinese guidelines yielded poor-to-moderate outcomes for NTM-PD in China, highlighting the need for further research into alternative antimicrobial treatments to improve efficacy.</p>","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 12","pages":"547-555"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11636495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}